Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Volunteers (Part 1) Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

NCT07214766
View directory record Official record
Conditions
Healthy Participants
Interventions
Trastuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Anaheim, California • Daytona Beach, Florida • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects

NCT02871037
View directory record Official record
Conditions
Normal Healthy
Interventions
PF-05221304, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

NCT03432884
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 21, 2026, 6:39 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

NCT02120976
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-252 or Placebo, JTT-252
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jul 21, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

NCT03852446
View directory record Official record
Conditions
Healthy
Interventions
Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jul 21, 2026, 6:39 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS

NCT07449572
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
HT31-1, Saline (0.9%, sterile, for infusion)
Drug · Other
Lead sponsor
HTIC, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

NCT01533155
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Nektar 118, Quinidine, Quinidine placebo, Morphine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers

NCT02690285
View directory record Official record
Conditions
Healthy
Interventions
Dichloroacetate (DCA), GSTZ1 haplotyping
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

NCT03723395
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

NCT05684289
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

NCT03801148
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of HU6

NCT06486558
View directory record Official record
Conditions
Healthy
Interventions
HU6 450 mg Tablet, HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Jul 21, 2026, 6:39 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib DDI Study With P-gp and BCRP Substrates

NCT05368805
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Fruquintinib, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 21, 2026, 6:39 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

NCT05521022
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
AT-02, AT-02 (Placebo)
Drug · Other
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Overland Park, Kansas • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Jul 21, 2026, 6:39 PM EDT